Abivax SA filings document the formal U.S. disclosure record of a France-based foreign private issuer and clinical-stage biotechnology company. Form 6-K reports cover current-event disclosures, annual meeting materials, shareholder voting matters, financial results, clinical and regulatory updates for obefazimod, and material agreements tied to the company’s capital structure.
The filing record also includes annual reporting on Form 20-F and references to Form F-3 and Form S-8 registration statements. These documents disclose Abivax’s research-and-development business, ADS and ordinary-share structure, financing activity, governance matters, risk factors, and regulatory reporting obligations in the United States.
Deep Track Capital, Deep Track Biotechnology Master Fund and David Kroin report joint beneficial ownership of 3,480,144 Abivax SA ordinary shares (represented by American Depository Shares), equal to 4.78% of the outstanding class. The filing shows 0 shares of sole voting or dispositive power and 3,480,144 shares of shared voting and dispositive power, with the percentage calculated from 72,784,660 ordinary shares outstanding per the issuer's disclosure.
The reporting persons state the securities were not acquired to change or influence control of the issuer (other than activities solely in connection with a nomination under applicable rules). The statement is filed jointly by the two Deep Track entities and David Kroin.